Clopidogrel

...arthritis, leukemia drug Sprycel and hepatitis B drug Baraclude. Plavix, the world's second-best-selling drug, had reported sales of $1.55 billion, up 8 percent. Most of that came from the U.S., where sales rose 11 percent, but sales...

In this article: Bristol-Myers, Revenue, Plavix, European Union, Abilify, U.S., Competitive advantage, and Bipolar disorder

Meanwhile, she said investor focus remains on cost savings, sales of four growth drivers - Plavix, Orencia for rheumatoid arthritis, leukemia drug Sprycel and combination HIV drug Atripla - along with some key drugs in development. Those...

In this article: Bristol-Myers, Plavix, Revenue, Abilify, Food and Drug Administration, AstraZeneca PLC, Bristol, Ipilimumab, and Otsuka Pharmaceutical Co.

...sales increases. Blood thinner Plavix, the world's number two drug, had sales of $1.55 billion, up 8 percent, plus additional income from Bristol's partnership with Sanofi-Aventis SA on foreign sales. Novartis posted a profit of...

In this article: Merck, Schering-Plough Corp, Revenue, Novartis AG, Januvia, Allergy, United States, Recession, and Tax

...sales, up 6%, and $699 million in Nutritional sales, down 6%. Growth in the pharmaceutical division was driven by strong sales of Plavix at $1,554 million, up 8%, HIV medication Sustiva at $315 million, up 7% and hepatitis B drug Baraclude...

In this article: Bristol-Myers Squibb, Revenue, Plavix, AstraZeneca plc, Bristol, Ipilimumab, LLY, Sanofi-Aventis, and Baraclude

...previously forecast $1.85 to $2. Quarterly sales of its biggest product, blood clot preventer Plavix that it markets in collaboration with Sanofi-Aventis SA <SASY.PA>, rose 11 percent to $1.54 billion. Several of its newer products...

In this article: Wyeth, Bristol-Myers, Revenue, Genentech, Sprycel, Bristol, Enbrel, and New York Stock Exchange

...whether Bristol can stave off generics to Plavix into the next decade. "Any bidder has to be comfortable with the patent protection for Plavix," Farrall said. Bristol has recently launched medicines for rheumatoid arthritis and...

In this article: Bristol, Sanofi-Aventis, Plavix, Cancer, Guidant, NEW YORK, Acomplia, and Avapro

...investigators. The toxicities involved multiple biological system and included thrombotic thrombocytopenic purpura (TTP) (ticlopidine and clopidogrel), thromboembolism (thalidomide and lenalidomide), hepatic failure (gemtuzumab and...

In this article: FDA, Thrombotic thrombocytopenic purpura, Conceptual framework, Causality, Tadalafil, Sildenafil, Ticlopidine, Nevirapine, and Lenalidomide

Bristol-Myers long been considered a leading takeover candidate, with some analysts suggesting the New York drugmaker would become a far more tempting target if it finds a way to better offset expected sales declines of Plavix. Under...

In this article: Bristol-Myers, Abilify, Plavix, Ixempra, United States, Revenue, and Zyprexa